74 FR 190 pg. 50960 - Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Novel Use and Method of Rapamycin To Treat Toxic Shock
Type: NOTICEVolume: 74Number: 190Page: 50960
FR document: [FR Doc. E9-23770 Filed 10-1-09; 8:45 am]
Agency: Defense Department
Sub Agency: Department of the Army
Official PDF Version: PDF Version
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Novel Use and Method of Rapamycin To Treat Toxic Shock
AGENCY:
Department of the Army, DoD.
ACTION:
Notice.
SUMMARY:
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/231,348 entitled "Novel Use and Method of Rapamycin to Treat Toxic Shock," filed August 5, 2009. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
ADDRESSES:
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION:
The invention relates to the use of Rapamycin as a treatment of toxic shock induced by staphylococcal exotoxins; more specifically, staphylococcal enterotoxins that are potent activators for human T cells and can cause lethal shock.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9-23770 Filed 10-1-09; 8:45 am]
BILLING CODE 3710-08-P